Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 1998

View Archived Issues

Company Profile: Vivus

Dainippon in-licenses Wakunaga fluoroquinolone

Bio-Technology General establishes Eastern European licensing agreement for recombinant insulin

Endorex, Elan agree to form joint venture for vaccine development

Merck continues to devote extensive R&D efforts to FTase inhibitors

Japanese launch announced for HIV protease inhibitor

Good in vitro activity reported for Novartis PKC inhibitor

First clinical results reported for SC-68240

Cell adhesion inhibitors from Merck KGaA

Chiroscience synthesizes new MMP/TNF-inhibitory agents

Ketoacid ETA antagonists from Warner-Lambert

Novel thalidomide prodrugs reported in patent literature

Neurogen describes D3 receptor-specific ligands

Novel binding mechanism described for Shin Nippon's H+/K+-ATPase inhibitor

Phase I/II results reported for Searle's new hematopoietic growth factor

New mycotoxin with antitumor and favorable hematological effects

New hematopoietic growth factor family presented

Effects of neutrophil elastase inhibitor MDL-101146 in two arthritis models

More dopamine receptor ligands from Merck & Co.

Diatide's acute thrombosis imaging agent scheduled for review by FDA panel

New urinary incontinence product from Biomatrix cleared for clinical trials

New antiviral peptides from Boehringer Ingelheim

Arris completes acquisition of Sequana

FDA approves Photofrin for early-stage lung cancer

Two SBIR grants awarded to Cubist for antiinfective drug discovery

Anti-HIV fusion inhibitor from Trimeris advances to phase II

CDK inhibitor induces apoptosis and tumor necrosis in a dog with malignant melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...